TW200602062A - Improved formulations of 6-mercaptopurine - Google Patents

Improved formulations of 6-mercaptopurine

Info

Publication number: TW200602062A
Authority: TW; Taiwan
Prior art keywords: mercaptopurine; improved formulations; formulations; improved; present
Prior art date: 2004-04-01

Application number

TW094110665A

Other languages

English (en)

Inventor

E Itzhak Lerner

Moshe Flashner-Barak

Erwin V Achthoven

Hans Keegstra

Ruud Smit

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-01

Filing date

2005-04-01

Publication date

2006-01-16

2005-04-01 Application filed by Teva Pharma filed Critical Teva Pharma

2006-01-16 Publication of TW200602062A publication Critical patent/TW200602062A/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW094110665A 2004-04-01 2005-04-01 Improved formulations of 6-mercaptopurine TW200602062A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US55847704P	2004-04-01	2004-04-01

Publications (1)

Publication Number	Publication Date
TW200602062A true TW200602062A (en)	2006-01-16

Family

ID=35150483

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW094110664A TW200602061A (en)	2004-04-01	2005-04-01	Delayed release formulations of 6-mercaptopurine
TW094110665A TW200602062A (en)	2004-04-01	2005-04-01	Improved formulations of 6-mercaptopurine

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TW094110664A TW200602061A (en)	2004-04-01	2005-04-01	Delayed release formulations of 6-mercaptopurine

Country Status (12)

Country	Link
US (2)	US20060008520A1 (zh)
EP (2)	EP1746975A2 (zh)
JP (2)	JP2007530693A (zh)
KR (4)	KR20100045528A (zh)
CN (2)	CN101146520A (zh)
AU (2)	AU2005232583B2 (zh)
CA (2)	CA2560654A1 (zh)
EA (2)	EA200601596A1 (zh)
IL (2)	IL178383A0 (zh)
MX (2)	MXPA06011316A (zh)
TW (2)	TW200602061A (zh)
WO (2)	WO2005099666A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200602061A (en) *	2004-04-01	2006-01-16	Teva Pharma	Delayed release formulations of 6-mercaptopurine
US8188067B2 (en) *	2004-04-01	2012-05-29	Teva Pharmaceutical Industries Ltd.	Formulations of 6-mercaptopurine
US8068569B2 (en)	2005-10-05	2011-11-29	Lg Electronics, Inc.	Method and apparatus for signal processing and encoding and decoding
CA2721728A1 (en)	2008-04-18	2009-10-22	Teva Pharmaceutical Industries Ltd.	Treatment of inflammatory bowel disease with 6-mercaptopurine
WO2010026993A1 (ja)	2008-09-03	2010-03-11	武田薬品工業株式会社	製剤における吸収性改善方法および吸収性が改善された製剤
EP2564838A4 (en)	2010-04-30	2014-06-04	Takeda Pharmaceutical	ENTERICIAN TABLET
US8920840B2 (en)	2010-04-30	2014-12-30	Takeda Pharmaceutical Company Limited	Enteric tablet
EP3362053A4 (en) *	2015-10-16	2019-04-17	Hadasit Medical Research Services and Development Ltd.	TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
CN108434109A (zh) *	2018-04-25	2018-08-24	首都医科大学附属北京儿童医院	微型巯嘌呤片、微型巯嘌呤肠溶缓释片、及其制备方法
CN108524463A (zh) *	2018-05-28	2018-09-14	浙江浙北药业有限公司	一种巯嘌呤组合物及其制备工艺
CN108553437A (zh) *	2018-06-08	2018-09-21	姚静	一种通过离子交换技术制得的巯嘌呤咀嚼片及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE23082E (en) *		1949-01-25		Grease compositions
US2697708A (en) *		1954-12-21		Z-mercapto-x-hydroxy-s-phenoxy pyrimi
BE627473A (zh) *	1962-01-24
US3548782A (en) *	1967-11-30	1970-12-22	Hanningsen Foods Inc	Means for forming a continuous coating on particles
US4059706A (en) *	1974-03-07	1977-11-22	General Foods Corporation	Spray-dried L-aspartic acid derivatives
DK172081A (da) *	1980-04-21	1981-10-22	Merck & Co Inc	Mercaptoforbindelse og fremgangsmaade til fremstilling deraf
DE3479423D1 (en) *	1984-02-29	1989-09-21	Covex Sa	Citrate of vinpocetine, and process for its preparation
GB8908229D0 (en) *	1989-04-12	1989-05-24	Smithkline Beckman Intercredit	Compounds
US5120740A (en) *	1989-11-03	1992-06-09	Wisconsin Alumni Research Foundation	Prodrugs of 6-mercaptopurine and 6-thioguanine
US5364646A (en) *	1990-01-10	1994-11-15	Dr. Karl Thomae Gmbh	Oral pharmaceutical forms of pimobendan
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
JP2538134B2 (ja) *	1991-04-08	1996-09-25	田辺製薬株式会社	徐放性製剤およびその製造法
US5370744B1 (en) *	1993-08-27	1999-11-09	Alcon Lab Inc	Process for cleaning and disinfecting contact lenses
US5691343A (en) *	1995-03-30	1997-11-25	Mayo Foundation For Medical Education And Research	Use of topical azathioprine to treat inflammatory bowel disorders
US5776431A (en) *	1997-03-26	1998-07-07	Galat; Alexander	Water-soluble aspirin composition
US6350470B1 (en) *	1998-04-29	2002-02-26	Cima Labs Inc.	Effervescent drug delivery system for oral administration
US6372254B1 (en) *	1998-04-02	2002-04-16	Impax Pharmaceuticals Inc.	Press coated, pulsatile drug delivery system suitable for oral administration
KR19990085365A (ko) *	1998-05-16	1999-12-06	허영섭	지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
DE19838540C2 (de) *	1998-08-25	2001-07-26	Herbert Huettlin	Verfahren zum Behandeln eines partikelförmigen Guts mit einem Überzugsmedium sowie Vorrichtung zur Durchführung eines derartigen Verfahrens
US6355623B2 (en) *	1998-09-24	2002-03-12	Hopital-Sainte-Justine	Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6602521B1 (en) *	1998-09-29	2003-08-05	Impax Pharmaceuticals, Inc.	Multiplex drug delivery system suitable for oral administration
ES2202069T3 (es) *	1999-03-19	2004-04-01	Ranbaxy Laboratories, Ltd.	Procedimiento para la preparacion de una forma de dosificacion oral biodisponible de axetil cefuroxima.
US7078057B2 (en) *	1999-12-20	2006-07-18	Kerkhof Nicholas J	Process for producing nanometer particles by fluid bed spray-drying
AU2001259706A1 (en) *	2000-05-09	2001-11-20	Reliable Biopharmaceutical, Inc.	Polymeric compounds useful as prodrugs
JP4803942B2 (ja) *	2000-05-19	2011-10-26	プロミシアスラボラトリーズ，インコーポレイテッド	チオプリンメチルトランスフェラーゼ活性を検出する方法
US6680068B2 (en) *	2000-07-06	2004-01-20	The General Hospital Corporation	Drug delivery formulations and targeting
US6692771B2 (en) *	2001-02-23	2004-02-17	Cima Labs Inc.	Emulsions as solid dosage forms for oral administration
US20030232760A1 (en) *	2001-09-21	2003-12-18	Merck & Co., Inc.	Conjugates useful in the treatment of prostate cancer
US6642276B2 (en) *	2001-10-01	2003-11-04	M/S Ind-Swift Limited	Controlled release macrolide pharmaceutical formulations
NZ534378A (en) *	2002-02-22	2006-10-27	Schering Corp	Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
DE10311729A1 (de) *	2003-03-18	2004-09-30	Schultheiss, Heinz-Peter, Prof. Dr.	Endovaskuläres Implantat mit einer mindestens abschnittsweisen aktiven Beschichtung aus Ratjadon und/oder einem Ratjadon-Derivat
US20050196418A1 (en) *	2004-03-04	2005-09-08	Yu Ruey J.	Bioavailability and improved delivery of alkaline pharmaceutical drugs
TW200602061A (en) *	2004-04-01	2006-01-16	Teva Pharma	Delayed release formulations of 6-mercaptopurine
US8188067B2 (en) *	2004-04-01	2012-05-29	Teva Pharmaceutical Industries Ltd.	Formulations of 6-mercaptopurine
US20050227689A1 (en) *	2004-04-13	2005-10-13	Jewett David T	Method and apparatus for automatic calibration of positioning system base stations
WO2006044202A2 (en) *	2004-10-19	2006-04-27	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid

2005
- 2005-04-01 TW TW094110664A patent/TW200602061A/zh unknown
- 2005-04-01 JP JP2007506315A patent/JP2007530693A/ja active Pending
- 2005-04-01 EA EA200601596A patent/EA200601596A1/ru unknown
- 2005-04-01 JP JP2007506314A patent/JP2007530692A/ja active Pending
- 2005-04-01 EP EP05767572A patent/EP1746975A2/en not_active Withdrawn
- 2005-04-01 WO PCT/US2005/011113 patent/WO2005099666A2/en not_active Ceased
- 2005-04-01 MX MXPA06011316A patent/MXPA06011316A/es active IP Right Grant
- 2005-04-01 CN CNA2005800171485A patent/CN101146520A/zh active Pending
- 2005-04-01 CA CA002560654A patent/CA2560654A1/en not_active Abandoned
- 2005-04-01 CA CA002560997A patent/CA2560997A1/en not_active Abandoned
- 2005-04-01 KR KR1020107007854A patent/KR20100045528A/ko not_active Withdrawn
- 2005-04-01 US US11/097,875 patent/US20060008520A1/en not_active Abandoned
- 2005-04-01 WO PCT/US2005/011112 patent/WO2005099665A2/en not_active Ceased
- 2005-04-01 TW TW094110665A patent/TW200602062A/zh unknown
- 2005-04-01 KR KR1020067020728A patent/KR100930329B1/ko not_active Expired - Fee Related
- 2005-04-01 AU AU2005232583A patent/AU2005232583B2/en not_active Ceased
- 2005-04-01 KR KR1020067020725A patent/KR20070007133A/ko not_active Abandoned
- 2005-04-01 MX MXPA06011317A patent/MXPA06011317A/es active IP Right Grant
- 2005-04-01 EA EA200601597A patent/EA200601597A1/ru unknown
- 2005-04-01 KR KR1020097013871A patent/KR20090081437A/ko not_active Withdrawn
- 2005-04-01 CN CNA2005800169983A patent/CN101065114A/zh active Pending
- 2005-04-01 EP EP05767549.8A patent/EP1729727B1/en not_active Expired - Lifetime
- 2005-04-01 AU AU2005232582A patent/AU2005232582B2/en not_active Ceased
2006
- 2006-09-28 IL IL178383A patent/IL178383A0/en unknown
- 2006-09-28 IL IL178384A patent/IL178384A/en active IP Right Grant
2008
- 2008-06-30 US US12/215,941 patent/US20090042914A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR100930329B1 (ko)	2009-12-08
EP1729727A2 (en)	2006-12-13
EP1746975A2 (en)	2007-01-31
US20090042914A1 (en)	2009-02-12
CN101146520A (zh)	2008-03-19
WO2005099666A3 (en)	2006-12-21
EA200601597A1 (ru)	2007-04-27
IL178384A (en)	2015-04-30
AU2005232582A1 (en)	2005-10-27
KR20090081437A (ko)	2009-07-28
KR20100045528A (ko)	2010-05-03
IL178383A0 (en)	2007-02-11
CN101065114A (zh)	2007-10-31
TW200602061A (en)	2006-01-16
CA2560997A1 (en)	2005-10-27
MXPA06011317A (es)	2007-04-02
WO2005099665A2 (en)	2005-10-27
KR20070026438A (ko)	2007-03-08
AU2005232583A1 (en)	2005-10-27
EP1729727B1 (en)	2019-07-03
CA2560654A1 (en)	2006-09-20
US20060008520A1 (en)	2006-01-12
AU2005232583B2 (en)	2009-03-12
WO2005099665A3 (en)	2007-01-11
JP2007530692A (ja)	2007-11-01
IL178384A0 (en)	2007-02-11
KR20070007133A (ko)	2007-01-12
EA200601596A1 (ru)	2007-04-27
MXPA06011316A (es)	2007-04-02
JP2007530693A (ja)	2007-11-01
WO2005099666A2 (en)	2005-10-27
AU2005232582B2 (en)	2009-05-21

Publication	Publication Date	Title
SG153800A1 (en)	2009-07-29	Pharmaceutical compositions
TW200732349A (en)	2007-09-01	Anti-OX40L antibodies and methods using same
LUC00065I2 (zh)	2018-03-28
MA28334A1 (fr)	2006-12-01	Compositions pharmaceutiques antivirales
TW200511992A (en)	2005-04-01	Sulfonamide substituted imidazoquinolines
AU2003280087A8 (en)	2004-01-19	Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
UA90875C2 (ru)	2010-06-10	Лекарственные формы пролонгированного действия, которые содержат ранолазин
MX2009013199A (es)	2010-01-15	Anticuerpos anti-notch1 nnr y sus metodos de uso.
MX266708B (es)	2009-06-24	Formulaciones de microparticulas de pantoprazol.
TW200510002A (en)	2005-03-16	Solid pharmaceutical preparation
TW200738751A (en)	2007-10-16	Anti-EphrinB2 antibodies and methods using same
NO20044898L (no)	2005-02-25	Nye etonogestrel estere
TW200602062A (en)	2006-01-16	Improved formulations of 6-mercaptopurine
ZA200604874B (en)	2007-03-28	Pharmaceutical compositions
TW200638932A (en)	2006-11-16	CCI-779 polymorph and use thereof
PL1713438T3 (pl)	2009-04-30	Mydło lecznicze
WO2006044548A3 (en)	2006-10-26	Clopidogrel compositions
AU2002361488A1 (en)	2004-07-22	Field and background of the invention
WO2006010077A3 (en)	2006-08-31	Prodrugs of lonidamine and lonidamine analogs
AU2002367159A1 (en)	2003-07-15	Field of the invention
GB0304681D0 (en)	2003-04-02	Radiolabelled structures
GB0208123D0 (en)	2002-05-22	The invention of business
GB0200631D0 (en)	2002-02-27	The invention of the destruction of the charm called Êg¨n sorÔ
GB0206335D0 (en)	2002-05-01	The invention of agricultural business
GB0206330D0 (en)	2002-05-01	The invention of feasibility